Robert Green, Division of Genetics, Brigham and Women's Hospital and Harvard Medical School; Associate Director for Research, Partners HealthCare Center for Personalized Genetic Medicine, Heidi Rehm, Chief Laboratory Director, Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine; Assistant Professor of Pathology, Harvard Medical School, and Daniel MacArthur, Assistant Professor, Harvard Medical School, discuss the impact genomics will have in the practice of medicine.
Robert C. Green, MD, MPH is a medical geneticist and a clinical researcher who directs the G2P research program (genomes2people.org) in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School. Dr. Green is principal investigator of the NIH-funded REVEAL Study involving randomized clinical trials to disclose a genetic risk factor for Alzheimer’s disease. He also co-directs the NIH-funded PGen Study, the first prospective study of direct-to-consumer genetic testing services and leads the MedSeq Project, the first NIH-funded research study to explore the use of whole genome sequencing in the clinical practice of medicine. Dr. Green is currently Associate Director for Research of the Partners Center for Personalized Genetic Medicine, and a Board Member of the Council for Responsible Genetics. He co-chairs the ACMG Working Group that is developing recommendations for management of incidental findings in clinical sequencing.
Daniel MacArthur, PhD is an Assistant Professor at Harvard Medical School, a group leader in the Analytic and Translational Genetics Unit at Massachusetts General Hospital, and an affiliate member of the Broad Institute of Harvard and MIT. His research focuses on the functional interpretation of large-scale human genome sequencing data, and the genetic diagnosis of rare, severe muscle diseases such as muscular dystrophy.
Heidi Rehm, Ph.D., FACMG is the Chief Laboratory Director for the Laboratory for Molecular Medicine at the Partners Healthcare Center for Personalized Genetic Medicine and Assistant Professor of Pathology at Harvard Medical School. The lab focuses on the rapid translation of new genetic discoveries into clinical tests that can be used to improve patient outcomes, supporting the model of personalized medicine. Dr. Rehm is involved in defining standards for the use of next generation sequencing in clinical diagnostics through her committee roles at the American College of Medical Genetics and collaborative efforts with the CDC. Dr. Rehm is also involved in a major effort to develop and curate a universal clinical genomic variant database through collaborative efforts with NCBI and many other groups. Dr. Rehm also conducts research in hearing loss, Usher syndrome, cardiomyopathy, and healthcare IT.
Robert Green and Heidi Rehm of the Partners Healthcare Center for Personalized Genetic Medicine discuss the recommendation to report back to patients genetic variants that were found while testing for something else.